^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:dasatinib (Multi-tyrosine kinase inhibitor) +
    Tasigna (nilotinib) (Bcr-abl inhibitor) +
    imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor) +
    S81694 (TTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

    Published date:
    11/06/2019
    Excerpt:
    Combination of S81694 with TKI imatinib, dasatinib and nilotinib (but not ponatinib) was strongly synergistic in BCR-ABL1+ cells (Figure 1H)….Mps1i S81694 yields significant preclinical activity in T-and B-cell ALL including BCR-ABL1+ models.
    DOI:
    https://doi.org/10.1182/blood-2019-125641